Page 52 - Read Online

Pica et al. Vessel Plus 2022;6:10 https://dx.doi.org/10.20517/2574-1209.2021.81 Page 11 of 11

33. Pan JA, Kerwin MJ, Salerno M. Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac
amyloidosis: a meta-analysis. JACC Cardiovasc Imaging 2020;13:1299-310. DOI PubMed PMC
34. Bandula S, Banypersad SM, Sado D, et al. Measurement of Tissue interstitial volume in healthy patients and those with amyloidosis
with equilibrium contrast-enhanced MR imaging. Radiology 2013;268:858-64. DOI PubMed PMC
35. Fontana M, Banypersad SM, Treibel TA, et al. AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect
different biology. J Cardiovasc Magn Reson 2014:16. DOI
36. Fontana M, Banypersad SM, Treibel TA, et al. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and
light-chain amyloidosis: a cardiac MR imaging study. Radiology 2015;277:388-97. DOI PubMed
37. Kotecha T, Martinez-Naharro A, Treibel TA, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol 2018;71:2919-
31. DOI PubMed
38. Sharpley FA, Fontana M, Martinez-Naharro A, et al. Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no
cardiac involvement by standard criteria. Haematologica 2020;105:1405-13. DOI PubMed PMC
39. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European
Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail 2021;23:512-26. DOI PubMed
40. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain
amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22
April 2004. Am J Hematol 2005;79:319-28. DOI PubMed
41. Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel
staging system. J Am Coll Cardiol 2016;68:1014-20. DOI PubMed
42. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39:2799-806.
DOI PubMed
43. Banypersad SM, Fontana M, Maestrini V, et al. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J
2015;36:244-51. DOI PubMed PMC
44. Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2,
T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the
European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 2017;19:75. DOI PubMed PMC
45. Law S, Petrie A, Chacko L, et al. Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National
Amyloidosis Centre transthyretin amyloidosis stage. ESC Heart Fail 2020;7:3942-9. DOI PubMed PMC
46. Raina S, Lensing SY, Nairooz RS, et al. Prognostic value of late gadolinium enhancement CMR in systemic amyloidosis. JACC
Cardiovasc Imaging 2016;9:1267-77. DOI PubMed
47. Boynton SJ, Geske JB, Dispenzieri A, et al. LGE provides incremental prognostic information over serum biomarkers in AL cardiac
amyloidosis. JACC Cardiovasc Imaging 2016;9:680-6. DOI PubMed
48. Lin L, Li X, Feng J, et al. The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance
imaging in patients with light chain amyloidosis. J Cardiovasc Magn Reson 2018;20:2. DOI PubMed PMC
49. Dorbala S, Vangala D, Bruyere J Jr, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and
function in cardiac amyloidosis. JACC Heart Fail 2014;2:358-67. DOI PubMed PMC
50. Chacko L, Kotecha T, Martinez-naharro A, et al. 1171Myocardial perfusion mapping in cardiac amyloidosis - exploring the spectrum
from infiltration to ischaemia. Eur Heart J 2019;40:ehz748.0013. DOI
51. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Blood 2020;136:2620-7. DOI PubMed
52. Addison D, Slivnick JA, Campbell CM, Vallakati A, Jneid H, Schelbert E. Recent advances and current dilemmas in the diagnosis and
management of transthyretin cardiac amyloidosis. J Am Heart Assoc 2021;10:e019840. DOI PubMed PMC
53. Martinez-Naharro A, Abdel-Gadir A, Treibel TA, et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC
Cardiovasc Imaging 2018;11:152-4. DOI PubMed
54. Maurer MS, Schwartz JH, Gundapaneni B, et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin
amyloid cardiomyopathy. N Engl J Med 2018;379:1007-16. DOI PubMed
55. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with
hereditary transthyretin-mediated amyloidosis. Circulation 2019;139:431-43. DOI PubMed
56. Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac
amyloid regression. JACC Cardiovasc Imaging 2021;14:189-99. DOI PubMed